Home > Healthcare > Healthcare IT > Payer/Provider Solutions > eClinical solutions Market
eClinical Solutions Market size was worth more than USD 8.7 billion in 2022 and is projected to witness a 9.9% CAGR between 2023 to 2032. Outsourcing of clinical trials to contract research organizations (CROs) to influence market growth.
Diversifying expertise of contract research organizations (CROs) has supported the outsourcing of clinical trials in recent years. The need for advanced medical equipment and pharmaceutical solutions has created the requirement for efficient, quick, and reliable clinical trial solutions. These trials are mostly time-consuming and need medical expertise to succeed. The Tufts Center for the Study of Drug Development states that approximately 7 out of 8 compounds that are put through clinical testing process fail.
Lack of knowledge about the advantages of eClinical solutions, especially among developing countries, may restrain market expansion. These solutions facilitate data exploration across various clinical studies and ensure patient safety and regulatory compliance using self-service exploratory analysis. However, the cost of upgrading eClinical software is high which is one of its biggest drawbacks. Furthermore, developing nations mostly have low disposable income with leads to reduced spending on healthcare.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
eClinical solutions Market Size in 2022: | USD 8.7 Billion |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 9.9% |
2032 Value Projection: | USD 23 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 190 |
Tables, Charts & Figures: | 313 |
Segments covered: | Solution, Delivery mode, Clinical trial phase, End-use and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
eClinical solutions market share from the randomization and trial supply management (RTSM) solution segment was nearly USD 1.5 billion in 2022. Randomization and Trial Supply Management (RTSM) system is essential for randomizing participants, distributing medications, and maintaining site supplies. It offers several advantages, including removing selection bias, balancing the group in terms of numerous known and unknown prognostic or confounding variables, and serving as the foundation for statistical tests.
Based on the delivery mode, eClinical solutions market from the web-hosted (On-Demand) solutions segment is expected to reach over USD 11.5 billion by 2032. These solutions have gained acceptance owing to their several benefits such as simple usability, accessibility, and comparatively minimal investment requirements. Web-hosted solutions maintain client data on cloud server which can be accessible easily through the web and only requires computer hardware with internet connectivity. These solutions are also simple to customize, allowing them to be tailored as per the requirement of customer groups.
eClinical solutions market from the Phase IV clinical trials segment is projected to surpass USD 4.5 billion by 2032. Phase IV clinical trials primarily study the long-term benefits and risks of using a drug. It checks the drug’s performance in real-life scenarios and identifies rare side effects. Also known as post-marketing surveillance study, these trials are carried out after the drug has already received approval and is readily available to the general population. The inclusion of a large number of participants in such clinical trials over a longer period will drive the need for eClinical solutions to make large volumes of data easily accessible.
Europe eClinical solutions market is predicted to be worth USD 5.4 billion by 2032 attributed to the rising government support for new medical R&D. The region also holds the presence of well-known eClinical solution firms such as Medidata Solutions, Inc., Veeva Systems, and DATATRAK. These companies are forming alliances with other related firms to support the deployment of eClinical solutions.
Some of the key participants in the global eClinical solutions market include
Companies are focusing on the development of new strategies to help support clinical trials in the coming years. For instance, in January 2021, Parexel International Corporation teamed up with Signify Health to include new clinical trials and develop the latest eClinical solutions. The aim was to provide access to clinical trials to a large pool of patients and to identify pertinent social determinants of health (SDoH) to promote links between patients, resources, and caregivers.
The COVID-19 pandemic forced several biopharmaceutical and medical device companies to put fresh clinical trials on hold. Many companies reduced or even stopped their R&D spending on clinical trials in comparison to pre-COVID levels because of the outbreak. This affected the outsourcing of clinical trials to CROs and caused a steep decline in revenue.
However, a rapid recovery was witnessed due to the emergence of new clinical trial models or techniques that use virtual trial tools such as analytically based software and data management. Many companies are inking partnership with virtual trial platform providers, eRecruitment providers, and remote monitoring solutions providers to improve their capacity to offer hybrid/distributed CT models.
Click here to Buy Section of this Report
By Solution
By Delivery Mode
By Clinical Trial Phase
By End-use
The above information is provided for the following regions and countries: